METHAMPHETAMINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Methamphetamine Hydrochloride, and when can generic versions of Methamphetamine Hydrochloride launch?
Methamphetamine Hydrochloride is a drug marketed by Able, Dr Reddys Labs Sa, Hikma, Rexar, and Teva. and is included in five NDAs.
The generic ingredient in METHAMPHETAMINE HYDROCHLORIDE is methamphetamine hydrochloride. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the methamphetamine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Methamphetamine Hydrochloride
A generic version of METHAMPHETAMINE HYDROCHLORIDE was approved as methamphetamine hydrochloride by DR REDDYS LABS SA on April 21st, 2010.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for METHAMPHETAMINE HYDROCHLORIDE?
- What are the global sales for METHAMPHETAMINE HYDROCHLORIDE?
- What is Average Wholesale Price for METHAMPHETAMINE HYDROCHLORIDE?
Summary for METHAMPHETAMINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 5 |
NDAs: | 5 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 31 |
Clinical Trials: | 141 |
Patent Applications: | 1,666 |
DailyMed Link: | METHAMPHETAMINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for METHAMPHETAMINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Florida | Early Phase 1 |
Carolyn Rodriguez | Phase 2 |
Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 |